R-CHOP versus R-CVP in the treatment of follicular lymphoma: A meta-analysis and critical appraisal of current literature

Journal of Hematology and Oncology

Volumn 2, Issue , 2009, Pages

  Siddhartha, Ganguly ^a   Vijay, Patel ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; COP PROTOCOL 2; MONOCLONAL ANTIBODY;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CARDIOTOXICITY; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FOLLICULAR LYMPHOMA; HUMAN; LONG TERM CARE; META ANALYSIS; OPEN STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RISK; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ALGORITHM; EVALUATION; REVIEW;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; EVALUATION STUDIES AS TOPIC; HUMANS; LYMPHOMA, FOLLICULAR; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE;

EID: 67651159290     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-2-14     Document Type: Article

References (15)

1. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993, 328:1002-1006.
2. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
3. Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999, 17:268-276.
4. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-López AJ: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow up. J Clin Oncol 2004, 22:4711-4716.
5. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, Wörmann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trümper L, Aldaoud A, Parwaresch R, Unterhalt M: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubucin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106:3725-3732.
6. Domingo-Domenech E, Gonzalez-Barca E, Estany C, Sureda A, Besalduch J, Fernandez de Sevilla A: Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas. Haematologica 2002, 87:1229-1230.
7. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P: CVP chemotherapy plus rituximab compared with CVP as firstline treatment for advanced follicular lymphoma. Blood 2005, 105:1417-1423.
8. Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, Greco FA, et al.: Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network. J Clin Oncol 2005, 23:1500-1506.
9. Herold M, Hieke K: Costs of drug delivery for CHOP, COP/CVP, and fludarabine: an international assessment. Value Health 2003, 6:167-174.
10. Falagas ME, Matthaiou DK, Bliziotis IA: The role of aminoglycosides in combination with a B-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. J Antimicrob Chemother 2006, 57:639-647.
11. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF: Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. QUO-RUM Group. Br J Surg 2000, 87:1448-1454.
12. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999, 17:1244-1253.
13. Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Forstpointner R, Nickenig C, Unterhalt M: Treatment strategies in follicular lymphomas: current status and future perspectives. J Clin Oncol 2005, 23:6394-6399.
14. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, Romaguera J, Rodriguez MA, Tsimberidou AM, Verstovsek S, Younes A, Pro B, Lee MS, Ayala A, McLaughlin P: Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M. D. Anderson Cancer Center. J Clin Oncol 2006, 24:1582-1589.
15. Niitsu N, Hayama M, Okamoto M, Khori M, Higashihara M, Tamaru J, Hirano M: Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patents with follicular lymphoma. Clin Cancer Res 2004, 10:4077-4082.